These contradictory findings of Drp1 inhibition to act as both pro-apoptotic and anti-apoptotic events in cancers cells may be attributed to the differences in the study model employed, chemotherapeutic agents used, treatment regimens, duration of experiment, types of apoptotic stimuli applied, signalling pathways being investigated, metabolic activity of tumours and/or stage of tumourigenesis. The gene discussed is DNM1L; the disease is cancer.